RedHill Biopharma Licenses FDA-Approved H. pylori Therapy Talicia For Middle East Expansion In Deal Valued At Up To $1.8M, Plus Tiered Sales Royalties

The deal aims to accelerate Talicia's entry into new Middle East markets 

Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months, plus a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales 

Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based therapy to address H. pylori antibiotic resistance. It is the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1and is first-line treatment listed in the American College of Gastroenterology (ACG) Clinical Guidelines2

H. pylori, a bacterial infection affecting >50% of the world's adult population3, and up to almost 80% in parts of the Middle East4, is a WHO-designated Group 1 carcinogen and key risk factor for gastric cancer5, which causes around 800,000 deaths globally6

Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation

RALEIGH, N.C., Oct. 6, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the licensing of Talicia for new Middle East markets in a deal worth potentially $1.8 million plus sales royalty payments.

Under the terms of the agreement, RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months. In addition, RedHill may receive a minimum of $1.3 million in near-term potential milestone payments, as well as tiered royalties up to mid-teens percent on Talicia net sales.